Desmoplastic infantile ganglioglioma
Desmoplastic infantile ganglioglioma (DIG) is a rare, benign brain tumor that primarily affects infants and young children. It is classified as a World Health Organization (WHO) Grade I tumor, indicating a low potential for malignancy. DIG is characterized by a combination of neuronal and glial cell components, along with a prominent desmoplastic (fibrous) stroma.
Clinical Presentation[edit]
Patients with desmoplastic infantile ganglioglioma typically present with symptoms related to increased intracranial pressure, such as vomiting, irritability, and macrocephaly. Seizures are also a common presenting symptom. The age of onset is usually within the first two years of life.
Pathology[edit]
Macroscopically, DIGs are large, cystic tumors with a solid component. Microscopically, they exhibit a mixture of ganglion cells, astrocytes, and a dense desmoplastic stroma. The presence of both neuronal and glial elements is a hallmark of this tumor type. Immunohistochemical staining often shows positivity for markers such as synaptophysin, neurofilament, and glial fibrillary acidic protein (GFAP).
Diagnosis[edit]
The diagnosis of desmoplastic infantile ganglioglioma is typically made through a combination of neuroimaging and histopathological examination. Magnetic resonance imaging (MRI) usually reveals a large, cystic mass with a solid component. Computed tomography (CT) scans may show calcifications within the tumor. Definitive diagnosis is confirmed through biopsy and subsequent histological analysis.
Treatment[edit]
The primary treatment for DIG is surgical resection. Complete removal of the tumor often results in a favorable prognosis. In cases where complete resection is not possible, additional treatments such as chemotherapy or radiation therapy may be considered, although their roles are not well established due to the tumor's rarity and generally benign nature.
Prognosis[edit]
The prognosis for patients with desmoplastic infantile ganglioglioma is generally good, especially when complete surgical resection is achieved. Recurrence is uncommon, and long-term survival rates are high. However, close follow-up is necessary to monitor for any signs of recurrence or complications.
Related Pages[edit]
- Brain tumor
- Neuronal tumor
- Glial cell
- Intracranial pressure
- Seizure
- Magnetic resonance imaging
- Computed tomography
- Surgical resection
References[edit]
External Links[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
